Abstract
Enfurvitide (T-20) inhibits one step of the fusion process between the HIV and the CD4 cell. Fusion, however, is only one part of a very complex process known as entry. Several novel antiretroviral classes and agents have been identified that could potentially inhibit different steps of this entry process. Candidates for drug development include chemokine receptor antagonists, CD4 receptor blockers, fusion inhibitors such as T-20, and antibodies against viral particles involved in the entry process. Among these classes, the chemokine receptor antagonists have yielded particularly promising results in early studies. Chemokine receptors are coreceptors that are required for HIV to bind to target cells. If the viral envelope surface glycoprotein gp120 does …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
